van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 2009;5:531–41.
Article
Google Scholar
McInnes IB, O’Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis. 2010;69:1898–906.
Article
CAS
Google Scholar
Mahajan TD, Mikuls TR. Recent advances in the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2018;30:231–7.
Article
CAS
Google Scholar
Chen Y-F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006;10:1–229.
Article
Google Scholar
Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339–53.
Article
CAS
Google Scholar
Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017;76:1113–36.
Article
Google Scholar
Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol. 2012;24:319–26.
Article
CAS
Google Scholar
Tanaka Y. Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis. 2013;72(Suppl 2):ii124–7.
Article
CAS
Google Scholar
Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
Article
CAS
Google Scholar
van Ingen ILA, Lamers-Karnebeek F, Jansen TL. Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase. Expert Opin Biol Ther. 2014;14:1761–7.
Article
Google Scholar
van den Broek M, Visser K, Allaart CF, Huizinga TWJ. Personalized medicine: predicting responses to therapy in patients with RA. Curr Opin Pharmacol. 2013;13:463–9.
Article
Google Scholar
Tweehuysen L, van den Ende CH, Beeren FMM, Been EMJ, van den Hoogen FHJ, den Broeder AA. Little evidence for usefulness of biomarkers for predicting successful dose reduction or discontinuation of a biologic agent in rheumatoid arthritis: a systematic review. Arthritis Rheumatol. 2017;69:301–8.
Article
Google Scholar
Saleem B, Keen H, Goeb V, Parmar R, Nizam S, Hensor EMA, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis. 2010;69:1636–42.
Article
Google Scholar
Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010;69:1286–91.
Article
CAS
Google Scholar
van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans HMJ, Kerstens PJSM, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis. 2011;70:1389–94.
Article
Google Scholar
Kavanaugh A, Lee SJ, Curtis JR, Greenberg JD, Kremer JM, Soto L, et al. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Ann Rheum Dis. 2015;7:1150–5.
Article
Google Scholar
Haschka J, Englbrecht M, Hueber AJ, Manger B, Kleyer A, Reiser M, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016;75:45–51.
Article
Google Scholar
Rech J, Hueber AJ, Finzel S, Englbrecht M, Haschka J, Manger B, et al. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis. 2015;75:1637–44.
Article
Google Scholar
Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux C-H, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Jt Bone Spine. 2009;76:350–5.
Article
CAS
Google Scholar
Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–79.
Article
CAS
Google Scholar
Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009;45:124–31.
Article
CAS
Google Scholar
Silva LCR, Ortigosa LCM, Benard G. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010;2:817–33.
Article
CAS
Google Scholar
Marotte H, Cimaz R. Etanercept - TNF receptor and IgG1 fc fusion protein: is it different from other TNF blockers? Expert Opin Biol Ther. 2014;14:569–72.
Article
CAS
Google Scholar
Kievit W, Adang EM, Fransen J, Kuper HH. Van de Laar M a FJ, Jansen TL, et al. the effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis. 2008;67:1229–34.
Article
CAS
Google Scholar
Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009;4:CD007848.
Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, et al. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial. Arthritis Rheumatol (Hoboken, NJ). 2016;68:1810–7.
Article
CAS
Google Scholar
Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified Disease Activity Scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
Article
CAS
Google Scholar
van der Maas A, Lie E, Christensen R, Choy E, de Man YA, van Riel P, et al. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Ann Rheum Dis. 2013;72:1800–5.
Article
Google Scholar
Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013;8:e60635.
Article
CAS
Google Scholar
Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, ten Klooster PM, Tekstra J, Schilder AM, et al. Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. PLoS One. 2018;13:e0192425. https://doi.org/10.1371/journal.pone.0192425.
Article
CAS
PubMed
PubMed Central
Google Scholar
Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2012;64:1794–803.
Article
Google Scholar
Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015;74:389–95.
Article
CAS
Google Scholar
Tanaka Y, Smolen J, Jones H, Szumski A, Marshall L, Emery P. Baseline characteristics and treatment outcomes of patients who achieve deep remission in rheumatoid arthritis. Ann Rheum Dis. 2016;75(Suppl 2):188.2–189.
Article
Google Scholar
Rosenthal JA. Qualitative descriptors of strength of association and effect size. J Soc Serv Res. 1996;21:37–59.
Article
Google Scholar
Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York, NY: John Wiley & Sons, Inc.; 2000.
Book
Google Scholar
Harigai M, Takeuchi T, Tanaka Y, Matsubara T, Yamanaka H, Miyasaka N. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol. 2012;22:814–22.
Article
Google Scholar
van der Helm-van Mil AHM, Knevel R, Cavet G, Huizinga TWJ, Haney DJ. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology (Oxford). 2013;52:839–46.
Article
Google Scholar
Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank SE, Sasso EH, Chernoff D, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis. 2015;74:1102–9.
Article
CAS
Google Scholar
Li W, Sasso EH, van der Helm-van Mil AHM, Huizinga TWJ. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. Rheumatology (Oxford). 2016;55:357–66.
Article
Google Scholar
Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M, et al. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther. 2018;20:165.
Article
Google Scholar
Curran-Everett D, Milgrom H. Post-hoc data analysis. Curr Opin Allergy Clin Immunol. 2013;13:223–4.
Article
Google Scholar